Expert on Demand in
non-small cell lung cancer (NSCLC)

The Expert on Demand programme at MSD provides an exciting opportunity for you and your multidisciplinary team to connect with experts in NSCLC at a time that works for you.

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) 
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website.

How to express your interest?

  • Choose your case study
  • Complete the form below to express your interest
  • You will be contacted by your local MSD representative to arrange a suitable time and date

Read more about the available modules in NSCLC below:

Module 1: Identification & Management of Immunotherapy Related Adverse Events in mNSCLC patients on KEYTRUDA (pembrolizumab) plus chemotherapy – A Multidisciplinary Perspective with Patient Case Studies

This module will explore data from KEYNOTE-189 (non-squamous mNSCLC) and KEYNOTE-407 (squamous mNSCLC), including a post-hoc exploratory pooled analysis of 5-year survival with pembrolizumab plus chemotherapy for mNSCLC patients with PD-L1 TPS <1%. An expert speaker will take you through the key data that impacts your day-to-day clinical decisions, including adverse event considerations. A complex non-squamous or squamous case study will be used to guide your discussion, and provide the opportunity for interactive learning.

Learning objectives:

Case studies available in module 1

Non-Squamous PD-L1 < 1% patient (Keynote-189): Skin toxicity case study – presented by Dr Toby Talbot

This session covers learnings and recommendations from a case study of an 81-year old female with non-squamous mNSCLC who was initiated on KEYTRUDA in combination with chemotherapy. The patient displayed a partial response but experienced skin toxicity, requiring the involvement of dermatology. Treatment was temporarily paused to manage the toxicity with steroids. Subsequently, the treatment was restarted.

Non-Squamous PD-L1 < 1% patient (Keynote-189): Pneumonitis case study – presented by Dr Spyros Gennatas

This session covers learnings and recommendations from a case study of an 76-year old female with non-squamous mNSCLC, emphysema, and type 2 diabetes treated with metformin. In late 2021, the patient was initiated on KEYTRUDA in combination with chemotherapy. The patient exhibited a partial metabolic response during the first four cycles. However, in June 2022, she presented with pneumonitis. Maintenance treatment was discontinued, and the pneumonitis was treated with steroids, resulting in complete resolution of signs and symptoms over three months. The patient continued undergoing surveillance but eventually demonstrated signs of progressive disease and was subsequently started on second-line therapy.

Squamous PD-L1 <1% patient (Keynote-407): Colitis case study – presented by Dr Toby Talbot

This session covers learnings and recommendations from a case study of an 50-year old female who initially presented in 2017 with locally advanced squamous NSCLC. They were initially treated with concurrent chemoradiotherapy. In September 2022, they experienced a relapse and were subsequently started on KEYTRUDA in combination with chemotherapy. Following the completion of four cycles, they transitioned to maintenance KEYTRUDA. However, in May 2024, treatment was paused as the patient developed significant diarrhoea and had a poor response to Loperamide. Gastroenterology was consulted, and the condition was ultimately managed as colitis with a tapering course of steroids. The patient’s diarrhoea resolved to grade 1, and treatment with KEYTRUDA was recommenced.

Speakers

Dr Toby Talbot

Dr Toby Talbot

Consultant Clinical Oncologist, Royal Cornwall Hospital

Biography

Dr Talbot studied medicine at University College London Medical School and graduated in 1999. He undertook specialist training in clinical oncology in the Southwest of England and became a consultant clinical oncologist at the Royal Cornwall Hospital in 2009, specialising in skin cancers, thoracic malignancies and sarcoma. He has a special interest in clinical research, particularly with immunotherapy and has been local principal investigator for over forty studies and national chief investigator on five trials. Outside of medicine, he enjoys beach and cliff walks and spending time on his smallholding looking after a variety of farm animals, bees and a large number of children.

Dr Spyros Gennatas

Dr Spyros Gennatas

Consultant Medical Oncologist, Guy’s and St Thomas’ Hospital NHS Foundation Trust

Biography

Spyros Gennatas has been a Consultant Medical Oncologist at Guy’s and St Thomas’ Hospital NHS Foundation Trust since 2021. He specialises in the treatment of thoracic malignancies, including lung cancer, thymic epithelial tumours and mesothelioma. He also works as a member of the acute oncology service at St Thomas’ Hospital and is the Acute Oncology Service clinical lead for Guy’s and St Thomas’. Spyros completed his medical oncology training at the Royal Marsden Hospital. He was awarded a PhD in the ‘Genetic alterations leading to thymic epithelial malignancies’, by Imperial College London (ICL) in 2018. During that time, he also worked as a research fellow for the National Mesothelioma Centre at ICL. He has published in high-impact, peer-reviewed journals and presented in international meetings in the fields of molecular genetics, quality of life in cancer patients, Covid-19 and cancer, and medical oncology.

KEYTRUDA, in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, is indicated for the treatment of resectable non-small cell lung carcinoma at high risk of recurrence in adults.1

KEYTRUDA as monotherapy is indicated for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum-based chemotherapy.1

KEYTRUDA as monotherapy is indicated for the first-line treatment of metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 with a ≥50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations.1

KEYTRUDA as monotherapy is indicated for the treatment of locally advanced or metastatic NSCLC in adults whose tumours express PD-L1 with a ≥1% TPS and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumour mutations should also have received targeted therapy before receiving KEYTRUDA.1

KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first‑line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations.1

KEYTRUDA, in combination with carboplatin and either paclitaxel or nab-paclitaxel, is indicated for the first-line treatment of metastatic squamous NSCLC in adults.1

The recommended dose of KEYTRUDA as monotherapy or as part of combination therapy is either 200 mg every 3 weeks or 400 mg every 6 weeks administered as an intravenous infusion over 30 minutes. KEYTRUDA should be administered first when given in combination with intravenous chemotherapy.1

Please refer to the SmPC for further information before making any prescribing decisions.

Reference

  1. KEYTRUDA Summary of Product Characteristics

To register your interest in Expert on Demand please complete the form below:

Read about the case studies here

MSD will only use this information for the purpose of responding to your inquiry and it will not be stored for any other use. MSD will not pass your information on to a third party organisation. This form is not intended for the reporting of adverse events or medical information.The reporting form and MSD Medical Information contact details can be found at the end of this page.

This field is for validation purposes and should be left unchanged.